SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Traders are debating whether Zoom can turn AI features into meaningful growth as competitors bundle similar tools and companies cut meeting seats alongside headcount. Skeptics see a mature, low-growth business with limited upsell potential, while some investors point to its AI strategy and valuation as reasons for optimism ahead of earnings.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on clinical updates for CRISPR Therapeutics gene-editing pipeline, particularly zugo-cels early autoimmune-disease results and the CTX310 cardiovascular program. Traders see the data as potential validation of the pipeline, while others caution that small patient groups, unresolved safety questions, and doubts about whether lipid reductions translate into clinical benefit temper enthusiasm; CASGEVYs commercial rollout is a secondary focus.

Direxion Shares ETF Trust - Direxion Daily Homebuilders & Supplies Bull 3X ETF

Direxion Daily Homebuilders & Supplies Bull 3X Shares

NAIL is drawing attention after a sharp homebuilder-sector rally followed by a pullback, with traders debating whether the move has further momentum or is due for a breather. The leveraged funds swings are closely tied to Treasury yields and mortgage-rate expectations, while some traders also point to call-heavy options activity.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Attention centers on povetacicepts upcoming FDA decision for IgA nephropathy, following positive Phase 3 RAINIER results; traders are bullish on its potential as a new growth pillar, though approval and commercial upside remain uncertain. Q3 results also drew mixed reactions, with revenue growth and raised guidance weighed against an adjusted EPS miss and concerns about valuation.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

A large, multi-year AST SpaceMobile agreement for Firefly engines, engine-technology licensing and engineering support is driving attention, with traders viewing it as a major backlog and technology-validation boost. The reaction is largely bullish after the sharp rally, though some question the deals cash-versus-stock terms and Fireflys ability to execute without dilution; NASA lunar-contract eligibility is a secondary positive theme.

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health Companies Inc

Bausch Healths stronger-than-expected third-quarter results and raised full-year outlook have driven a sharp rally, with traders also pointing to debt reduction and a share repurchase authorization. The reaction is broadly bullish, though some remain cautious about the companys heavy debt burden and are taking profits; speculation about changes involving Bausch + Lomb remains unconfirmed.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Nasdaq-linked attention is centered on volatility and a tech-led pullback, with traders debating whether rate concerns, AI-stock selling and geopolitical risks signal a deeper correction or a buying opportunity. Some posts also point to Nasdaqs earnings and planned extended-hours trading, but the broader discussion is split between bearish caution and dip-buying optimism.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWXTs quarterly results are driving discussion: traders weigh an adjusted-EPS beat against a revenue miss, debating whether the weak reaction reflects valuation concerns or a buying opportunity. Some see its naval-nuclear backlog and commercial reactor and fuel prospects as longer-term support.

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Attention centers on Corcepts strong Q3 results and the upcoming FDA decision on relacorilant for Cushings syndrome. Traders are weighing the companys growing Lifyorli business against concerns that Genmabs ovarian-cancer drug could intensify competition, with disagreement over whether the selloff overstates that risk.

Direxion Shares ETF Trust - Direxion Daily GOOGL Bull 2X ETF

Direxion Daily GOOGL Bull 2X Shares ETF

Traders are using GGLLs leveraged exposure to Alphabet to play GOOGLs rally, citing optimism around its AI and cloud business and recent momentum. Dip-buying and bullish calls dominate, though some traders point to put activity and warn of pullbacks and leverage risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corcepts Q3 report and rapid Lifyorli launch growth are drawing attention, though the shares remain weak after a steep pullback. Traders debate whether unchanged full-year guidance and competition from Genmabs Rina-S temper the outlook, while watching the upcoming FDA decision on relacorilant for Cushings syndrome.

CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues

Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates

Corcept (CORT) delivered earnings and revenue surprises of +48.53% and +3.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the...

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information...

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from...

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American...

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.

The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics

Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics earn top Zacks rankings, backed by growth drivers ranging from streaming ads to drug demand.

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.


3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge 

As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.

These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright raised CORT’s price target to $165 from $95 and maintained a ‘Buy’ rating, according to The Fly.</li><li>Corcept reported second-quarter revenue of $256.1 million, up 32% year over year.</li><li>B. Riley raised ANIK’s price target and maintained a ‘Buy’ rating, citing improved margins and structural cost improvements that could support long-term profitability.</li></ul>Corcept Therapeutics (CORT) and Anika Therapeutics (ANIK) hit fresh 52-week highs on Thursday, with CORT recording its biggest single-day gains in nearly 16 months, following price target hikes on Wall Street after a better-than-expected second-quarter print.At the time of writing, <a href="https://stocktwits.com/symbol/CORT">CORT stock</a> was up 27% while <a href="https://stocktwits.com/symbol/ANIK">ANIK shares</a> gained 13%.<h2 class="st-heading-2">Wall Street Sees 40% Upside Potential In CORT Stock After Q2 Earnings Beat</h2>Corcept Therapeutics received major Wall Street support after reporting strong second-quarter results and sharply raising its 2026 outlook. H.C. Wainwright raised its price target to $165 from $95 and maintained a ‘Buy’ rating, according to The Fly. The firm said Corcept has evolved into a multi-product company with its expansion into oncology.Piper Sandler also lifted its target to $165 from $88 and kept an ‘Overweight’ rating. The price targets imply a 40% upside potential from current levels.Corcept reported revenue of $256.1 million, up 32% year over year and above analysts’ expectations of $221.2 million, according to Fiscal.ai.&nbsp;Earnings came in at $0.36 per share, significantly ahead of the $0.02 estimate.Korlym and its authorized generic drug to treat Cushing’s syndrome generated $208.6 million in revenue, while ovarian cancer treatment Lifyorli contributed $47.6 million. The company also increased its 2026 revenue guidance to $1.1 billion to $1.2 billion, up from $950 million to $1.05 billion previously.Retail sentiment surrounding CORT on Stocktwits&nbsp;flipped to ‘extremely bullish’ from ‘neutral’ a day earlier, amid a 5,300% increase in message volumes. The stock has soared more than 210% so far this year.<h2 class="st-heading-2">B. Riley Sees Long-Term Profitability Prospects For ANIK</h2>Anika Therapeutics received price-target hikes after reporting stronger-than-expected second-quarter results and raising its 2026 outlook.B. Riley raised its price target to $21 from $18 and maintained a ‘Buy’ rating, citing improved margins, commercial growth, and structural cost improvements that could support long-term profitability.Barrington also lifted its target to $21 from $17 and kept an ‘Outperform’ rating, pointing to the quarterly earnings beat, higher full-year guidance, and strong international momentum.On Wednesday, Anika reported second-quarter revenue of $32.6 million, up from $28.2 million a year earlier and ahead of analysts’ $29.2 million estimate, according to Fiscal.ai. The company earned $0.42 per share, comfortably beating the $0.03 consensus estimate. Anika also raised its 2026 revenue growth guidance to 5% to 10%, up from the previous 1% to 9% range.Retail sentiment surrounding ANIK on Stocktwits remained in the ‘bearish’ territory over the past 24 hours, amid ‘high’ message volumes. The stock has surged more than 95% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-launches-shelf-obesity-drug-study-q2-results/cZN5etIRJcz">VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corcept Therapeutics logo is seen displayed on the screen of a tablet

Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.

Anika Therapeutics Inc.

SPDR S&P Biotech ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$72.77
Prev Close	$71.63
Open	$73.60
Dividend Yield	0.00%
50-Day Moving Average	$107.58
Beta	1.50
Avg. Volume	931,058.29
PE Ratio	57.43

52-Week High	$126.38
52-Week Low	$28.66
Market Capitalization	$7.96B
EPS (Annual)	$0.8182
Price to Book	9.55
Revenue Per Employee	$1.04M

Feed

News

Sentiment

Earnings

Fundamentals

Info

CORT Fundamentals